Results 81 to 90 of about 39,319 (333)

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

Journal of Clinical Oncology, 2021
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia ...
W. Wierda, J. Allan, T. Siddiqi, T. Kipps, Stephen Samuel Opat, A. Tedeschi, X. Badoux, B. Kuss, S. Jackson, C. Moreno, R. Jacobs, J. Pagel, I. Flinn, Y. Pak, Cathy Zhou, E. Szafer-Glusman, J. Ninomoto, J. Dean, D. James, P. Ghia, C. Tam   +20 more
semanticscholar   +1 more source

Ibrutinib-related uveitis: A case series

American Journal of Ophthalmology Case Reports, 2022
Purpose: Four cases of ibrutinib-related uveitis are presented, which are to the best of our knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are explored.
Zelia K. Chiu, Jonathan KS. Goh, Cecilia Ling, Ming-Lee Lin, Anthony J. Hall   +4 more
doaj  

Regulation of B cell fate by chronic activity of the IgE B cell receptor. [PDF]

, 2016
IgE can trigger potent allergic responses, yet the mechanisms regulating IgE production are poorly understood. Here we reveal that IgE+ B cells are constrained by chronic activity of the IgE B cell receptor (BCR).
Allen, Christopher DC, Chen, Xiangjun, Liu, Wanli, Robinson, Marcus J, Smith, Geoffrey A, Taunton, Jack, Yang, Zhiyong   +6 more
core   +1 more source

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Blood Advances, 2023
Key Points • Ibrutinib ± rituximab was effective and well tolerated as first-line MCL therapy; outcomes were worse in patients with high-risk disease.• Novel approaches are needed for patients with high-risk MCL and those with progressive disease after ...
A. Tivey, R. Shotton, T. Eyre, D. Lewis, Louise Stanton, Rebecca Allchin, Harriet Walter, F. Miall, Rui Zhao, A. Santarsieri, R. McCulloch, M. Bishton, A. Beech, V. Willimott, Nicole Fowler, Claudia Bedford, Jack Goddard, Samuel Protheroe, Angharad Everden, D. Tucker, Joshua Wright, Srivasavi Dukka, Miriam Thomson, S. Paneesha, M. Prahladan, Andrew Hodson, I. Qureshi, M. Koppana, Mary Owen, Kushani Ediriwickrema, H. Marr, Jamie Wilson, Jonathan Lambert, D. Wrench, C. Burney, Chloe Knott, G. Talbot, A. Gibb, Angela Lord, Barry Jackson, Simon Stern, Taylor Sutton, Amy Caitlin Webb, Marketa Wilson, Nicky Thomas, J. Norman, E. Davies, Lisa Lowry, Jamie Maddox, N. Phillips, N. Crosbie, Marcin Flont, Emma Lm Nga, A. Virchis, R. Guerrero Camacho, Wunna Swe, Arvind R Pillai, Clare Rees, James Bailey, S. G. Jones, Susan Smith, F. Sharpley, C. Hildyard, S. Mohamedbhai, T. Nicholson, S. Moule, Anshuman Chaturvedi, K. Linton   +67 more
semanticscholar   +1 more source

Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

Journal of Hematology & Oncology, 2022
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are ...
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse   +44 more
doaj   +1 more source

Characterization of the effects of BTK inhibition and monocyte-produced IL-8 on the hematopoietic stem cell niche [PDF]

, 2020
Hematopoietic stem and progenitor cells (HSPCs) are multipotent stem cells that give rise to all blood cell lineages. During early zebrafish development, HSPCs interact closely with endothelial cells in an endothelial niche known as the Caudal ...
Belardo, Alexander
core  

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Leukemia, 2023
Chronic lymphocytic leukemia (CLL) cells upregulate Bcl-2 proteins within the lymph node (LN) microenvironment. Signaling via B-cell receptor, Toll-like receptors and CD40 collectively reduce sensitivity to the BCL-2 inhibitor venetoclax.
K. Kielbassa, M. Haselager, Danique J. C. Bax, Bianca F. van Driel, J. Dubois, M. Levin, S. Kersting, R. Svanberg, C. Niemann, A. Kater, E. Eldering   +10 more
semanticscholar   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

Ibrutinib:
From Molecule to Medicine

International Journal of Hematology and Oncology, 2014
Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is a novel targeted-therapeutic agent modulating BCR, which serves as a covalent irreversible inhibitor of BTK. Ibrutinib significantly alters the composition of the tumor microenvironment in CLL, affecting soluble as well as cellular molecular elements without myelosupression. Ibrutinib is
Demirkan, Fatih, Ayyildiz, Orhan, Unal, Ali, KAYNAR, Leylagül, Vural, Filiz, Turgut, Mehmet, ŞAHİN, FAHRİ, SAYINALP, NİLGÜN, SAYDAM, GÜRAY, Ozdemir, Evren, Ilhan, Osman, Haznedaroglu, Ibrahim C., GÖKER, HAKAN   +12 more
openaire   +4 more sources

Ibrutinib is not an effective drug in primografts of TCF3-PBX1

Translational Oncology, 2020
Aim: The Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib (PCI-32765) is effective in patients with multiple myeloma, non-Hodgkin lymphoma and chronic lymphoblastic leukemia. We previously showed that primary cells of children with TCF3-PBX1 positive B-
Cesca van de Ven, Aurélie Boeree, Femke Stalpers, C. Michel Zwaan, Monique L. Den Boer   +4 more
doaj